相关实验视频

Updated: Jul 11, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在病理性阴性节点非小细胞肺癌中辅助化疗

Ya-Fu Cheng¹, Yi-Ling Chen², Chia-Chi Liu¹

¹Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, No. 135 Nanxiao St., Changhua City, Changhua County, 500, Taiwan.

Scientific reports

|November 6, 2023

概括

辅助化疗可能有利于患有较大的非小细胞肺癌 (NSCLC) 瘤 (4厘米以上) 和差异化瘤的患者. 对于较小的瘤 (3-4厘米),生存益处并不显著.

科学领域:

在瘤学瘤学.
胸部外科手术胸部外科手术
癌症研究癌症研究

背景情况:

非小细胞肺癌 (NSCLC) 即使在早期阶段,也构成了严重的生存挑战.
准确识别可能受益于手术后辅助化疗的病态N0 NSCLC患者对于改善结果至关重要.

研究的目的:

为了评估辅助化疗在手术切除后患有病态N0NSCLC的患者的疗效.
确定瘤大小和分化是否影响pN0 NSCLC中辅助化疗的益处.

主要方法:

使用监测,流行病学和最终结果 (SEER) 数据库进行回顾性队列研究.
包括26380名患有病态N0NSCLC的患者进行手术 (2018-2019).
1:1的倾向性比分匹配,比较单独的手术 (2107名患者) 与手术加辅助化疗 (2107名患者).

主要成果:

辅助化疗没有显著改善T2aN0NSCLC的24个月生存率 (83.41%对比82.91%,p=0.067).
在接受辅助化疗的T2bN0NSCLC患者中观察到显著的生存益处 (86.36%与81.70%,p=0.028).
差差分化的NSCLC是pT2N0阶段的高风险因素,辅助化疗显示出匹配后的生存率有所改善 (86.36%vs81.70%,p=0.029).

结论:

辅助化疗在pN0 NSCLC患者中表现出有益作用,瘤大小超过4厘米.
辅助化疗的影响对于3至4厘米之间的瘤来说不那么明显.
差异化组织结构是pT2N0 NSCLC的重要风险因素,辅助化疗可能会改善这些病例的结果.

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...